Cooperative Agreement U01CA291884
Award Date
9/15/24
Completion Date
8/31/29
Dollars Obligated
$268K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
Great Britain, United Kingdom
Similar Awards
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will provide $811,500.00 over a 5-year period beginning September 1, 2024 to develop and implement a comprehensive platform for patient-specific mechanistic tumor modeling. The key products and services to be delivered include: Merging bioinformatics software for single-cell and spatial multi-omics data analysis (COGAPS, PROJECTR, SPACEMARKERS, DOMINO) with the PhysiCell agent-based...
The National Institutes of Health (NIH) awarded a $797,648 Cooperative Agreement under the Trans-NIH Research Support program (CFDA 93.310) to the University of Florida. The award aims to establish a BSSR (Behavioral and Social Science Research) Ontology Development Network with a Dissemination and Coordination Center (DCC) to facilitate collaboration, provide technical support, and develop resources for expanding and using BSSR ontologies. The DCC, led by the University of Florida, will: 1)...
This Cooperative Agreement award for $416,745.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports the development of an "Integrative Analysis and Visualization Platform for Cancer Regulatory Genomics." The key products to be delivered under this award include: Creation of a "Regulatory-Element-Target-Gene Atlas" to enable researchers to explore connections between regulatory elements and cancer-associated genes (Aim 1). Analysis...
The National Cancer Institute (NCI) awarded a 5-year, $846,735 Cooperative Agreement under the Cancer Biology Research (CFDA 93.396) federal grant program to the Research Foundation of the City University of New York (RFCUNY) to maintain and expand the core Bioconductor software infrastructure for advanced cancer genomics research. The project aims to: 1) enhance infrastructure for multimodal experiments and spatial transcriptomics, integrating Bioconductor with image analysis tools; 2)...
The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $639,964 Cooperative Agreement to the University of Wisconsin-Madison to evaluate implementation strategies for promoting smoking cessation treatment and cancer prevention services for clients of the Salvation Army. The project aims to refine and test two implementation approaches: 1) a sustained collaborative model to support Salvation Army staff in connecting clients to the...
This federal Cooperative Agreement award was provided by the National Center for Complementary and Integrative Health (NCCIH) under the Research and Training in Complementary and Integrative Health (CFDA 93.213) grant program. The $671,176 award will fund the development and validation of comprehensive knowledge resources and natural language processing (NLP) methods for mining the literature on complementary medicine (CM) approaches, including their mechanisms of biological action. The...
This Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program provides $653,951 to implement and evaluate smoking cessation interventions for people with HIV in Laos. The two-arm pragmatic clinical trial will compare the reach and effectiveness of an Ask-Advise-Connect approach paired with either a mobile health program or printed self-help materials. The project aims to increase smoking cessation rates, reduce...
This federal Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, will provide $720,252 to the Dana-Farber Cancer Institute, Inc. (DFCI) from April 1, 2025 to March 31, 2030. The project aims to characterize the genetic risk of cancer across diverse populations through multi-ancestry epigenome profiling and chromatin QTL discovery. Key objectives include: 1) Identifying chromatin QTLs (cQTLs) that confer...
This $172,197 Project Grant award, funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to establish and refine processes that facilitate clinical trials in cancer interception (prevention) at the University of Kansas Cancer Center (KUCC). The key objectives are to: Hire project navigators to facilitate study approvals for principal investigators outside the KUCC oncology department. Train research coordinators in cancer prevention trials....
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, aims to improve the measurement of cancer registry completeness. The $653,500 award, with a performance period from September 15, 2024 to August 31, 2029, will fund the development of new methods to estimate cancer registry completeness that account for demographic and geographic factors. This will allow cancer registries to better identify...